河北医学2016，Vol.22Issue(8)：1268-1270,1271,4.DOI:10.3969/j.issn.1006-6233.2016.08.014
EGFR－TKI 联合同步放疗治疗 EGFR 突变型转移性非小细胞肺癌的疗效及安全性评价
Efficacy and Safety Evaluation of EGFR-TKI with Concurrent Radiotherapy in the Treatment of EGFR Mutant Metastatic Non-small Cell Lung Cancer
摘要
Abstract
Objective: To evaluate the efficacy and safety of EGFR -TKI with concurrent radiotherapy in the treatment of EGFR mutant metastatic non -small cell lung cancer.Methods:The clinical data of 60 cases of patients with EGFR mutant metastatic non -small cell lung cancer in our hospital from March 2011 to March 2014 were statistically analyzed.Results:The total effective rate of the combination therapy group 83.3%(25 /30) was significantly higher than the monotherapy group 53.3% (16/30) (P <0.05), the PFS, OS were sig-nificantly longer (P <0.05), the 1 year, 2-year survival rate 66.7% (20/30), 13.3% (4/30) were signifi-cantly higher than the monotherapy group 43.3% (13/30), 3.3% (1/30) (P <0.05), but the differences of the rates of adverse events of rash, diarrhea, nausea, vomiting, fatigue, anemia, leukopenia, thrombocytope-nia, radiation pneumonitis, esophagitis, radiation encephalopathy between the two groups were not significant (P>0.05).Conclusion:EGFR-TKI with concurrent radiotherapy in the treatment of EGFR mutant metastatic non-small cell lung cancer is safe and effective .关键词
EGFR-TKI联合同步放疗/EGFR突变型转移性非小细胞肺癌/疗效Key words
EGFR -TKI with concurrent radiotherapy/EGFR mutant metastatic non -small cell lung cancer/Efficacy引用本文复制引用
俞卫卫,周锡建,周道安,潘德键,周仁贵..EGFR－TKI 联合同步放疗治疗 EGFR 突变型转移性非小细胞肺癌的疗效及安全性评价[J].河北医学,2016,22(8):1268-1270,1271,4.基金项目
江苏大学医学临床科技发展基金， （）
